Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI +1.43%53 Degree of Financial Leverage is 1.82 as of Mar. 2026. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,342 Biotechnology companies, Puma Biotechnology ranks worse than 83.61% on this metric.
Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT).
Puma Biotechnology's Degree of Financial Leverage for the quarter that ended in Mar. 2026 was 1.82. The higher Degree of Financial Leverage, the more volatile earnings will be.
The industry rank for Puma Biotechnology's Degree of Financial Leverage or its related term are showing as below:
PBYI's Degree of Financial Leverage is ranked worse than 83.61% of 1342
companies
in the Biotechnology industry
Industry Median: 0.94
vs PBYI: 1.82
Puma Biotechnology (NAS:PBYI) Degree of Financial Leverage Explanation
Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.
The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.
Be Aware
The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.
Puma Biotechnology Degree of Financial Leverage Related Terms
Puma Biotechnology Degree of Financial Leverage Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Degree of Financial Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology Degree of Financial Leverage Chart
PBYI vs EVMN, OCGN, EDIT: Degree of Financial Leverage Comparison
For the Biotechnology subindustry, Puma Biotechnology's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology Degree of Financial Leverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Degree of Financial Leverage distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Degree of Financial Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Financial Leverage of 1.82 mean?
Puma Biotechnology (PBYI) has a Degree of Financial Leverage of 1.82 as of Mar. 2026. Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in EBIT. View historical data for Puma Biotechnology and its competitors. According to the industry distribution chart, Puma Biotechnology ranks #1122 out of 1342 companies in the Biotechnology industry, placing it in the top 83.6%.
Is Puma Biotechnology's Degree of Financial Leverage too high?
Puma Biotechnology's current Degree of Financial Leverage is 1.82. The Biotechnology industry median Degree of Financial Leverage is 0.94. Puma Biotechnology's value of 1.82 is 93.6% above this industry median. Based on the distribution chart, Puma Biotechnology ranks #1122 out of 1342 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Degree of Financial Leverage compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #1122 out of 1342 companies for Degree of Financial Leverage. This places Puma Biotechnology in the lower half of its industry. The industry median Degree of Financial Leverage is 0.94. Puma Biotechnology's value of 1.82 is 93.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Financial Leverage for a Biotechnology company?
The median Degree of Financial Leverage among Biotechnology companies is 0.94, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Financial Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Financial Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current Degree of Financial Leverage of 1.82 is 93.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Financial Leverage mean?
A high Degree of Financial Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in EBIT. View historical data for Puma Biotechnology and its competitors. For the Biotechnology industry, the median Degree of Financial Leverage is 0.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current Degree of Financial Leverage is 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.80 — trading 133.5% above its estimated fair value. The current Degree of Financial Leverage is 1.82 and 93.6% above the Biotechnology industry median of 0.94. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Financial Leverage calculated?
Degree of Financial Leverage is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Degree of Financial Leverage is 1.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.80 is trading 133.5% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Degree of Financial Leverage: 1.82
GF Value™: $3.34 vs. price of $7.80 (133.5% above fair value)
Industry Position: 93.6% above the Biotechnology median (#1122 of 1342)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Degree of Financial Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
